i checked on trendlyne. At screenshot the quantity at NSE is 7.5 & at BSE it is also 7.5.
Posts tagged Value Pickr
Hitesh portfolio (23-06-2024)
Your query has been beautifully answered by @barathmukhi . Fully agree with his views. The other aspect of the equation is to figure out where you are extremely good at. Whether its technical analysis or fundamental analysis. And follow that discipline.
Its not possible for me to give personalised advice on a particular stock. You can take your own call.
Alembic Pharma (Oral Solids ==> Injectables, Onco, Derma, Opthalmic) (23-06-2024)
Here are my notes from their AR24.
Manufacturing facilities:
-
All EIRs are in place
-
F1 (Panelav): Oral solids
-
F2 (Panelav): Oncology oral solids + oncology injectables
-
F3 (Karkhadi): General injectables+ Ophthalmic
-
F4 (Jarod): Oral solids + Oral suspensions. Transferred products from F1 to F4 to decongest F1
-
F5 (Karkhadi): Dermatology
-
Sikkim: Branded domestic business
-
Pithampur will come onstream in FY25 and complement Sikkim for domestic sales
-
3 API plants (2 in Panelav, 1 in Karkhadi)
US (sales: 1’730 cr., growth @10%)
-
Launched 27 products (15 were from new facilities), filed 15 ANDAs (12 complex filings), got 15 final approvals, filed 1 DMF
-
10 injectables launched so far
-
Reduced annual ANDA filings from 20-25 earlier to 15 now, product mix is changing to complex products
-
7 oncology product filings awaiting approvals
-
Filings catering to new therapies (oncology, dermatology and ophthalmology) and new platforms (injectables and inhalation) it stood 12 filings (out of 15 filings) in FY24. In FY25, the filings for these products and platforms will be ~14
-
54% of development pipeline for the US comprises non-OSD products
-
Made a meaningful entry into the peptide space with 2 ANDAs filed and setting up a kilo lab for peptide APIs
Non-US generic (sales: 1’052 cr., growth @23%)
-
14 launches in FY24
-
Will launch 25+ products in Chile in FY25 expanding product basked to 30+. Expect to start operations in Mexico in 2026
-
Received orders for 2 injectables from Malaysia and Chile which will be launched in FY25
-
Setup subsidiary in UAE with a scientific office. Filed 20 products in UAE and hopeful of securing approvals in 12-18 months
-
Have presence in 41 countries
-
Their strategy of developing B2B model has worked well in Europe
-
Favorable regulatory tailwinds in Australia helped them grow volumes
Domestic business (sales: 2’200 cr., growth @7% vs 8% for industry)
-
12 therapeutic areas, 20 marketing divisions, 5000+ MRs catering to 2.33 lakh doctors (vs 2.31 lakh in FY23)
-
Launched 15-20 new products
-
1.5% market share, 4 brands generating 100 cr.+ revenues, 9 leading brands, 69 brands above 10 cr. sales
-
MRs 5000+, gave iPads to MRs and upgraded to SalesForce
API (sales: 1’246 cr., growth @7%)
- 33% captive consumption
Animal healthcare
-
Created a new division for livestock products, 71 products launched in speciality and animal health spaces in FY23 and FY24.
-
Expanded team to 350 people
R&D 476 cr. (vs 731 cr. in FY23)
-
Investments in API, injectables and ophthalmic will increase
-
Largest investment in FY25 will be on peptide-based formulations and APIs for Para-IV filings
-
6 new technologies such as powder drug layering, laser drilled osmotic drug delivery, spray drying, hot melt extrusion, wet milling using Dyno-mill and dry granulation using roller compactor were introduced
-
New technologies to manufacture various dosage forms are through the technology of sterile powder namely lipid-based liposomes and polymer based microspheres. Nanoparticle delivery system technology is also introduced that uses nanoparticles for targeted administration and controlled release of therapeutic agents. Device capabilities have been introduced for manufacturing pre-filled syringes, pre-filled cartridges, pens and auto-injectors both upstream and downstream
-
800+ R&D team
Capex (345 cr.)
-
Capex cycle is over fulfilling demand over next 3-5 years, expect good free cashflow generation
-
Setup 12MW solar power plant for Panelav unit, setting up 11MW solar plant at Karakhadi in FY25
Miscellaneous
-
Employees : 14’858 (vs 14’593 in FY23)
-
KMP + close person remuneration: 75 cr. (vs 48 cr. in FY23)
-
Related party purchases from Shreno Publications: 50.95 cr. (vs 43.31 cr. in FY23)
-
CSR : Spent 13.19 cr. (transferred 2.94 cr. of obligations in April 2024)
-
8% increase for non-managerial personnel and 65% increase for managerial personnel (there was no commission paid in FY23 which was reinstated resulting in higher payout to KMPs)
-
# shareholders : 78’191 (vs 101’761 in FY23)
-
Auditor remuneration : 1.39 cr. (vs 1.3 cr. in FY23)
-
Tax liability : 13.22 cr. (vs 1.77 cr. in FY23)
-
Contingent liability : No major liability except corporate guarantee of 40.69 cr. (vs 106.72 cr. in FY23)
Disclosure: Invested (position size here, no transactions in last-30 days)
Basilic Fly Studio Ltd (22-06-2024)
BFS stock price has increased ~20% in last 5 days, does anyone know what is going on? Cannot find any news or announcements around it.
Smallcap momentum portfolio (22-06-2024)
@visuarchie sir, the Z-score strategy was not included in the pure momentum strategy because it is often considered more of a statistical method used to identify overbought or oversold conditions rather than a primary momentum strategy. Most momentum strategies focus on trend following and relative strength, which are easier to understand and implement for many investors.
As you know Z-score Strategy measures how far a data point (stock price) is from the mean, expressed in terms of standard deviations. A high Z-score might indicate overbought conditions, while a low Z-score suggests oversold conditions.
- This strategy can help identify potential reversals rather than pure momentum plays.
In contrast, traditional momentum strategies like trend following, relative momentum, and sector rotation are more directly aligned with the core concept of momentum investing, which is capitalizing on stocks that are already trending upward or downward.
For those interested in momentum investing, combining the Z-score with other momentum strategies might offer additional insights and enhance overall performance. The Z-score can act as a complementary tool to identify extremes and potential mean-reversion points within a broader momentum framework.
Your input please, why not other strategy than z score which you follow, please.
Shankara Build Pro – Building Materials Organised Retail (22-06-2024)
I was going through the Annual Report 23-24 consolidated P/L statement and found that there is an interest expense of 27Cr. while total borrowing of the company is only 83Cr. as per consolidated Balance Sheet. This amounts to around 32% cost of borrowings annually, similar to credit cards! I could not find any explanation regarding high interest expense by going through the notes. Is this really correct or am I missing something?
Antony Waste – Long Term (22-06-2024)
Likely Deducted from Deferred Tax Asset. Company had paid extra tax in the past, they’re deducting it now.
Jagsonpal Pharmaceuticals – What is driving the price? (22-06-2024)
Just want to share few points which may be relevant in the future of this company :-
1 Mr Manish Gupta, Md had purchased 1.62 % equity of the company in Feb 2022 ie before joining the company as MD @ Rs 235/share… He joined as MD in Aug 22.
2 May be Mr Manish Gupta was instrumental in Purchase of 43% shares by the Infinity Holding arond the same price.
3 Yash pharma acquired by JPL at 2 times P/S which has given exposure to Derma and childcare. Sharing the link of the presentation about both the companies.
Hope to see good growth in top line and the margins keeping in view the past track record of MD.
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4e8819fe-ac27-486d-a702-78c42da4ea1b.pdf
Annapurna Swadisht Ltd – A Swadisht FMCG investment? (22-06-2024)
ANNAPURNA_21062024195640_Intimation_under_Regulation_30.pdf (549.1 KB)
Preferential allotment of 6,00,000 shares @ Rs.295/-
Lazycap’s Portfolio – Feedback (22-06-2024)
Update
Entered GPT healthcare with 3.5% position on folio cost basis at 156. Seems like a good bet considering it is one the undervalued ones in Hospital. Good capex plans going ahead, will add more once convinced of prospects or thinking to play as a basket with likes of HCG/Aster/Shalby/Narayana
I like GPT though, I have not studied others much I just know them on the surface level, As GPT is already at medium cost basis for patients I am hoping if any regulations are enforced in terms of pricing of procedures at hospitals this one might turnout to be least affected (no numbers support as such just a though derived from what I saw in Management interviews)